New Concepts in Antihypertensive Drug Therapy. In: Morganroth J, Moore EN, editors. Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia. Boston: Springer US; 1990. pp. 3-12. [DOI: 10.1007/978-1-4613-1505-6_1]

Neutral endopeptidase inhibitors and atrial natriuretic peptide

A limited number of ectoenzymes appear to be involved in the inactivation of circulating-regulatory peptides. Neutral endopeptidase 24.11, a metallopeptidase, is known to inactivate atrial natriuretic peptide (ANP), a substance with diuretic, natriuretic, and vasodilatory effects. Synthetic inhibitors of endopeptidase 24.11, which can prolong the activity of ANP, are currently available. These agents are being evaluated as possible innovative therapies for patients with hypertension and congestive heart failure.